Aardvark Therapeutics (AARD) Receivables (2025)

Aardvark Therapeutics (AARD) posted Receivables of $1.4 million for Q3 2025, little changed sequentially from $1.4 million in Q2 2025.

Aardvark Therapeutics (AARD) Receivables (2025) Analysis & Trends

Aardvark Therapeutics has reported Receivables for 1 years, with the latest figure at $1.4 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.93 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	912.74 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	215.33 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.09 Bn
10	Aardvark Therapeutics	127.36 Mn	53.44 Mn	-	-

Download Data